Rare Birds in North America: Acute Hepatitis C Cohorts

• Type of Material: Article
• Authors: Andrea L. Cox, Johns Hopkins University; Kimberly Page, University of California, San Francisco; Julie Bruneau, Centre de Recherche du Centre Hospitalier de l’Université de Montréal; Naglaa H. Shoukry, Centre de Recherche du Centre Hospitalier de l’Université de Montréal; Georg M. Lauer, Massachusetts General Hospital; Arthur Y. Kim, Massachusetts General Hospital; Hugo R. Rosen, University of Colorado Health Sciences University; Hank Radziewicz, Emory University; Arash Grakoui, Emory University; Daniel S. Fierer, Mount Sinai School of Medicine; Andrea D. Branch, Mount Sinai School of Medicine; David E. Kaplan, University of Pennsylvania; Kyong-Mi Chang, University of Pennsylvania
• Language: English
• Date: 2009-01-01
• Publisher: Elsevier: 12 months
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1053/j.gastro.2008.11.049
• Title of Journal or Parent Work: Gastroenterology
• ISSN: 0016-5085
• Volume: 136
• Issue: 1
• Start Page: 26
• End Page: 31
• Grant/Funding Information: The work with this cohort has been funded by NIH DA016156 and DK066939.
• Keywords: PD-1 EXPRESSION; Science & Technology; Gastroenterology & Hepatology; RECOVERY; THERAPY; Life Sciences & Biomedicine; VIRAL PERSISTENCE; ESCAPE; T-CELL RESPONSES; ACUTE HCV INFECTION; VIRUS-INFECTION
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

In this issue of Gastroenterology, the Comment from the Editor highlights 8 cohorts of patients with acute hepatitis C virus (HCV) infection and the dedicated investigators who are tracking these rarely identified patients in variety of unusual settings—collectively identifying 643 patients since 1996 as summarized in Table 1. The identification, enrollment, prospective monitoring, and treatment of patients with acute HCV infections require enormous collaborative efforts and networking among individuals and institutions in addition to multiple sources of research funding.